← Back to Cases
PMCPA Case

Takeda: Clinical trial disclosure (Vipidia) — No breach, outwith scope (AUTH/2907/11/16)

📅 2016 | 🖉 Dr Anzal Qurbain
📊

Key facts

⌄
Case numberAUTH/2907/11/16
PartiesDirector v Takeda
IssueClinical trial disclosure (Vipidia)
Complaint received06 December 2016
Completed17 March 2017
OutcomeNo breach; outwith the scope of the Code
Clauses citedNot stated
SanctionsNot stated
ProductVipidia
Sourcehttps://www.pmcpa.org.uk/cases/completed-cases/auth29071116-director-v-takeda

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

⌄
  • A matter was considered by the PMCPA involving the Director and Takeda.
  • The case related to clinical trial disclosure for Vipidia.
  • Complaint received: 06 December 2016.
⚖️

Outcome

⌄
  • No breach.
  • Outwith the scope of the Code.
  • Case completed: 17 March 2017.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access
← All Cases Book a Free Compliance Call

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training